SE9000532L - Farmaceutisk tclf-komposition - Google Patents

Farmaceutisk tclf-komposition

Info

Publication number
SE9000532L
SE9000532L SE9000532A SE9000532A SE9000532L SE 9000532 L SE9000532 L SE 9000532L SE 9000532 A SE9000532 A SE 9000532A SE 9000532 A SE9000532 A SE 9000532A SE 9000532 L SE9000532 L SE 9000532L
Authority
SE
Sweden
Prior art keywords
human
tclf
ebv
cell lines
human cell
Prior art date
Application number
SE9000532A
Other languages
English (en)
Swedish (sv)
Other versions
SE9000532D0 (sv
Inventor
M Mitsuhashi
Original Assignee
Hayashibara Biochem Lab
Mochida Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP56112913A external-priority patent/JPS5816687A/ja
Priority claimed from JP56112914A external-priority patent/JPS5815921A/ja
Priority claimed from JP56120459A external-priority patent/JPS5821621A/ja
Priority claimed from JP56187627A external-priority patent/JPH0764744B2/ja
Priority claimed from JP56187626A external-priority patent/JPS5889195A/ja
Priority claimed from JP56205115A external-priority patent/JPS6011890B2/ja
Application filed by Hayashibara Biochem Lab, Mochida Pharm Co Ltd filed Critical Hayashibara Biochem Lab
Publication of SE9000532D0 publication Critical patent/SE9000532D0/xx
Publication of SE9000532L publication Critical patent/SE9000532L/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SE9000532A 1981-07-21 1990-02-14 Farmaceutisk tclf-komposition SE9000532L (sv)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP56112913A JPS5816687A (ja) 1981-07-21 1981-07-21 リンホトキシンの製造方法
JP56112914A JPS5815921A (ja) 1981-07-21 1981-07-21 抗リンホトキシン感受性疾患剤
JP56120459A JPS5821621A (ja) 1981-07-31 1981-07-31 ヒトツモア・ネクロシス・ファクタ−を含有する悪性腫瘍治療剤
JP56187627A JPH0764744B2 (ja) 1981-11-21 1981-11-21 標的細胞障害性因子とヒトインタ−フェロンとを有効成分として含有する悪性腫瘍治療剤
JP56187626A JPS5889195A (ja) 1981-11-21 1981-11-21 標的細胞障害性因子の製造方法
JP56205115A JPS6011890B2 (ja) 1981-12-21 1981-12-21 ツモアネクロシスフアクタ−の製造方法

Publications (2)

Publication Number Publication Date
SE9000532D0 SE9000532D0 (sv) 1990-02-14
SE9000532L true SE9000532L (sv) 1991-08-15

Family

ID=27552385

Family Applications (2)

Application Number Title Priority Date Filing Date
SE8204382A SE8204382L (sv) 1981-07-21 1982-07-19 Sett att framstella malcellysfaktor och anvendning derav
SE9000532A SE9000532L (sv) 1981-07-21 1990-02-14 Farmaceutisk tclf-komposition

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SE8204382A SE8204382L (sv) 1981-07-21 1982-07-19 Sett att framstella malcellysfaktor och anvendning derav

Country Status (9)

Country Link
US (1) US4495282A (xx)
AT (1) AT387980B (xx)
AU (1) AU560793B2 (xx)
CH (1) CH664974A5 (xx)
DE (1) DE3227262C3 (xx)
FR (1) FR2513124B1 (xx)
GB (1) GB2106117B (xx)
IT (1) IT1196549B (xx)
SE (2) SE8204382L (xx)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5821621A (ja) * 1981-07-31 1983-02-08 Hayashibara Biochem Lab Inc ヒトツモア・ネクロシス・ファクタ−を含有する悪性腫瘍治療剤
US4920196A (en) * 1982-07-30 1990-04-24 Genentech, Inc. Human lymphotoxin
US4806471A (en) * 1982-09-16 1989-02-21 A/S Alfred Benzon Plasmids with conditional uncontrolled replication behavior
ZA844070B (en) * 1983-06-01 1984-12-24 Genentech Inc Gamma interferon-lymphotoxin synergism
CA1265444A (en) * 1983-06-27 1990-02-06 Lloyd J. Old Effect of human tumor necrosis factor and human interferon on human cancer cells and methods
JPS6019720A (ja) * 1983-07-14 1985-01-31 Yamanouchi Pharmaceut Co Ltd ヒト内来性癌制御因子およびその製造法
JPS60112718A (ja) * 1983-11-21 1985-06-19 Kyorin Pharmaceut Co Ltd 抗腫瘍作用を示す蛋白性物質及びその製造方法
EP0147689B1 (en) * 1983-12-05 1990-09-19 Asahi Kasei Kogyo Kabushiki Kaisha A method of inducing antitumor immunocytes, and a process for producing antitumor immunocytes and antitumor immunocytes produced by the process
HU192254B (en) * 1983-12-13 1987-05-28 Egyt Gyogyszervegyeszeti Gyar Process for producing human leucocite and human gamma interferons in consecutive steps
US4758549A (en) * 1983-12-13 1988-07-19 Kabushiki Kaisha Mayashibara Seibutsu Kagaku Kenkyujo Lymphokine, monoclonal antibody specific to the lymphokine and their production and uses
US5288852A (en) * 1984-03-06 1994-02-22 Dainippon Pharmaceutical Co., Ltd. Human tumor necrosis factor polypeptides
US4879226A (en) * 1984-04-06 1989-11-07 Asahi Kasei Kogyo Kabushiki Kaisha Novel human physiologically active polypeptide
JPS60243018A (ja) * 1984-05-17 1985-12-03 Yamanouchi Pharmaceut Co Ltd ヒト内来性癌制御因子
US5683688A (en) * 1984-05-31 1997-11-04 Genentech, Inc. Unglycosylated recombinant human lymphotoxin polypeptides and compositions
DE3423234A1 (de) * 1984-06-23 1986-02-06 Boehringer Ingelheim International GmbH, 6507 Ingelheim Synergistische mischungen von interferonen und tumor-nekrose-faktor
US6686455B1 (en) 1984-07-05 2004-02-03 Genentech, Inc. Tumor necrosis factor
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
JPS6124520A (ja) * 1984-07-12 1986-02-03 Takeshi Makitsubo 腫瘍壊死因子様物質を抽出する方法
GB2161813B (en) * 1984-07-20 1988-07-13 Michiko Koga Anti-tumor agent
US5840522A (en) * 1984-09-20 1998-11-24 Chiron Corporation Recombinant lectins
US4677064A (en) * 1984-11-09 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4677063A (en) * 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4752575A (en) * 1984-11-26 1988-06-21 The Regents Of The University Of California Lymphotoxins with antitumor activity and method for producing same
EP0216786B1 (en) * 1984-12-21 1992-03-18 Biogen, Inc. Purification, production and use of tumor necrosis factors
PT81823B (pt) * 1985-01-14 1987-11-30 Yamanouchi Pharma Co Ltd Metodo de preparacao de factores endogenos humanos reguladores de cancro
US4900724A (en) * 1985-03-04 1990-02-13 Sawai Pharmaceutical Co., Ltd Tumor necrosis factor inducing substance derived from acid-fast bacteria
US6084073A (en) * 1985-03-25 2000-07-04 Chiron Corporation Recombinant ricin toxin
US4770995A (en) * 1985-08-29 1988-09-13 New York Blood Center, Inc Detection of the sensitivity of cells to the effects of tumor necrosis factor and lymphotoxin
US4870163A (en) * 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
US4894439A (en) * 1986-05-22 1990-01-16 Cetus Corporation N-terminal derivatives of tumor necrosis factor purified by microporous PTFE membranes
US4677197A (en) * 1985-10-30 1987-06-30 Cetus Corporation Purification method for tumor necrosis factor
US4828830A (en) * 1986-01-24 1989-05-09 Genentech, Inc. Method and composition for prophylaxis and treatment of viral infections
NZ219027A (en) * 1986-01-24 1989-09-27 Genentech Inc Antiviral composition containing interferon tumour necrosis factor and/or lymphotoxin
US4822605A (en) * 1986-02-18 1989-04-18 Exovir, Inc. Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like
US4777242A (en) * 1986-10-10 1988-10-11 Phillips Petroleum Company Purification of recombinant tumor necrosis factor
US5213970A (en) * 1987-01-23 1993-05-25 Board Of Regents, The University Of Texas System Method for obtaining soluble antitumor factor
US4975377A (en) * 1987-05-14 1990-12-04 Key Marc E Cell growth chambers and method of use thereof
DE3731255A1 (de) * 1987-09-17 1989-04-06 Boehringer Ingelheim Int Stabilisierung von therapeutisch wirksamen proteinen in pharmazeutischen zubereitungen
WO1990000400A1 (en) * 1988-07-15 1990-01-25 The Trustees Of Columbia University In The City Of New York Tumor necrosis enhancing factor and methods of preparation and use
US6617171B2 (en) * 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
US6599710B1 (en) 1999-03-10 2003-07-29 The General Hospital Corporation Treatment of autoimmune disease
JP4177604B2 (ja) * 2002-03-25 2008-11-05 株式会社林原生物化学研究所 生理活性複合体
US7179891B2 (en) 2002-03-25 2007-02-20 Tadanori Mayumi Physiologically active complex
US7628988B2 (en) 2002-06-27 2009-12-08 The General Hospital Corporation Methods and compositions for treating type 1 diabetes
US7582313B2 (en) * 2002-06-27 2009-09-01 The General Hospital Corporation Methods of organ regeneration using Hox 11-expressing pluripotent cells
WO2004045376A2 (en) * 2002-11-15 2004-06-03 The General Hospital Corporation Screening methods to identify treatments for autoimmune disease
ES2347239T3 (es) * 2002-12-02 2010-10-27 Amgen Fremont Inc. Anticuerpos dirigidos al factor de necrosis tumoral y usos de los mismos.
US20080102054A1 (en) * 2005-01-18 2008-05-01 Faustman Denise L Compositions Containing Agm Cells And Methods Of Use Thereof
EP3936137A1 (en) 2013-02-07 2022-01-12 The General Hospital Corporation Methods for expansion or depletion of t-regulatory cells
US10436680B2 (en) 2013-10-15 2019-10-08 Kianoosh Peyvan Capture, disruption, and extraction apparatus and method
HRP20231392T1 (hr) 2015-05-15 2024-04-26 The General Hospital Corporation Antagonistička protutijela na superobitelj receptora za faktor tumorske nekroze
EP3355914B1 (en) 2015-09-29 2024-03-06 The General Hospital Corporation A composition comprising bcg for reducing cholesterol.
CN116715767A (zh) 2016-05-13 2023-09-08 综合医院公司 拮抗性抗肿瘤坏死因子受体超家族抗体
CN108576399A (zh) * 2018-03-22 2018-09-28 中国农业科学院生物技术研究所 复合干扰素组合物及其制剂和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2016015B (en) * 1978-01-22 1982-05-06 Hayashibara Co Method of preparing interferon and preparations containing interferon
DE2961658D1 (en) * 1978-05-17 1982-02-18 Thomae Gmbh Dr K Process for preparing human interferon
JPS5598118A (en) * 1979-01-18 1980-07-25 Hayashibara Takeshi Preparation of type-2 interferon and drug containing the same
JPS55154919A (en) * 1979-05-24 1980-12-02 Hayashibara Takeshi Preparation of interferon
US4328207A (en) * 1979-12-27 1982-05-04 Ken Hayashibara Process for preparing mouse interferon
JPS586475B2 (ja) * 1980-08-23 1983-02-04 株式会社 林原生物化学研究所 ヒト絨毛性性腺刺激ホルモンの製造方法
JPS6045849B2 (ja) * 1980-08-25 1985-10-12 林原 健 ヒトエリトロポエチンの製造方法
JPS5743696A (en) * 1980-08-27 1982-03-11 Hayashibara Biochem Lab Inc Preparation of human luteinizing hormone
JPS585671B2 (ja) * 1980-08-27 1983-02-01 株式会社 林原生物化学研究所 ヒト卵胞刺激ホルモンの製造方法

Also Published As

Publication number Publication date
GB2106117B (en) 1985-06-12
CH664974A5 (fr) 1988-04-15
AU560793B2 (en) 1987-04-16
DE3227262C3 (de) 1996-03-21
DE3227262A1 (de) 1983-03-03
SE8204382L (sv) 1983-01-22
FR2513124A1 (fr) 1983-03-25
IT1196549B (it) 1988-11-16
DE3227262C2 (xx) 1988-11-17
GB2106117A (en) 1983-04-07
US4495282A (en) 1985-01-22
FR2513124B1 (fr) 1989-11-17
SE9000532D0 (sv) 1990-02-14
ATA283582A (de) 1988-09-15
AU8620082A (en) 1983-01-27
IT8248855A0 (it) 1982-07-20
SE8204382D0 (sv) 1982-07-19
AT387980B (de) 1989-04-10

Similar Documents

Publication Publication Date Title
SE9000532L (sv) Farmaceutisk tclf-komposition
Cheever et al. Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2.
DE68926859T2 (de) Natürlicher killerzellen-stimulationsfaktor
US5457038A (en) Natural killer stimulatory factor
KR930701601A (ko) O-글리코실화 ifn-알파
PT93910A (pt) Prodesso para a preparacao de uma proteina heterologa mediante secrecao a partir de uma celula
DE68926971D1 (de) Klonierte gene, die für elam-1 und für dessen fusionsproteine kodieren sowie die exprimierten proteinprodukte, pharmazeutische zusammensetzungen und deren verwendung
ATE67504T1 (de) Insulin-receptor, seine reinigung, seine herstellung in rekombinanten zellen, dna hierfuer, antikoerper gegen den insulin-receptor und deren herstellung, sowie pharmazeutische zusammensetzungen, die diese antikoerper enthalten.
US5811523A (en) Antibodies to natural killer stimulatory factor
IT1131325B (it) Procedimento per ridurre la solubilita' di setacci molecolari zeolitici in un sistema acquoso
FI883688A (fi) Molekylaer kloning och expression av humant interleukin-3.
EP0291804A3 (de) Proteine mit TNF-Wirkung
FI945696A0 (fi) Laktaamidipeptidejä, joilla on HLE:a inhiboiva aktiivisuus
ATE64579T1 (de) Schwimmbadwasserbehandlung.
JPS5562024A (en) Preventive and remedy for interferon-sensitive disease
Low et al. Thymosin and other thymic hormones and their synthetic analogues
FI946202A (fi) Fluoria sisältäviä dipeptidejä inhibiittoreina ihmisen lenkosyyttielastaasi-inhibiittoreita vastaan
Murphy et al. The turnover catabolism and excretion of folate administered at physiological concentrations in the rat
ITOH et al. Purification of a cytotoxic protein produced by the murine macrophage-like cell line J774. 1 in response to Sarcophaga lectin
FR2624885B1 (fr) Ensemble electrodes-electrolyte polymere solide utilisable par exemple pour l'electrolyse de l'eau, et son procede de fabrication
Godard et al. Preparative two-step purification of human IL-2 by HPLC and hydrophobic affinity chromatography
Jasin et al. Effects of L-asparaginase on in vitro immunoglobulin synthesis by rat spleen cells
ATE346921T1 (de) Menschliches, durch kalzium aktivierbares kaliumkanalpolypeptid aus leukozyten
FI914160A0 (fi) Analysis och behandling av auto- immuniska sjukdomar.
Geczy Characterization of guinea pig mitogenic factors—II: A comparison of some biochemical parameters of mitogen-induced and antigen-induced factors

Legal Events

Date Code Title Description
NAV Patent application has lapsed

Ref document number: 9000532-3